



# SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

SPIL/CS/SE/2025-2026/14

Date: 13<sup>th</sup> May 2025

To,

**The Listing Department**

**BSE Limited**

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INE00TV01023

Sub: **Updates on acquisition of the Share Capital of Cibachem General Trading L.L.C., Dubai, United Arab Emirates**

Ref: **Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

In continuation of the Company's disclosure dated 16<sup>th</sup> January 2025 (SPIL/CS/SE/2024-25/54 regarding approval of the Board to acquire 300 shares of face value of AED 1,000/- each of M/s. Cibachem General Trading L.L.C., Dubai, United Arab Emirates ('Cibachem') (License no.: 696207) equivalent to 100.00% of the paid up share capital of Cibachem at a consideration of Rs.25,00,000/- or its equivalent foreign exchange in UAE Dirhams (AED), this is to inform you that the Directors of the Company have at their meeting held on 13<sup>th</sup> May, 2025 resolved to acquire the said 300 shares of face value AED 1,000/- each of M/s. Cibachem General Trading L.L.C. at a revised consideration of Rs.55,00,000/- or its equivalent foreign exchange.

The details required under Regulation 30 of the SEBI Listing Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November, 2024 are given as Annexure A.

The meeting of the Board of Directors commenced at 11.00 am and concluded at 11.30 am.

This is for your information and record.

Thanks & Regards,

Yours faithfully,

For, Sudarshan Pharma Industries Limited

Nirav Shah

Company Secretary & Compliance Officer



Encl: As above



# SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

## Annexure-A

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024 are given below:

Sl. No.	Details to be Provided	Information
1	Name of the target entity, details in brief such as size, etc.	<b>Name:</b> Cibachem General Trading L.L.C. ( <b>Cibachem</b> )  Cibachem General Trading L.L.C, a limited liability company established originally under the name "Benjamin International General Trading L. L. C. under The Federal Law no. 8 of 1984 and registered with the Department of Economic Development of the Emirate of Dubai under commercial license no. 696207 and attested by the Notary Public under serial no. 172562/1/2013 on 30 <sup>th</sup> September 2013.
2	Whether the acquisition would fall within related party transactions and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length'	No.  The acquisition would not fall within the related party transactions.
3	Industry to which the entity being acquired belongs.	Cibachem was established to carry on the business of general trading which shall include the carrying on of all activities as are related or ancillary thereto except that Cibachem cannot carry on the business of insurance, banking or investment of funds for the account of third parties.
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The acquisition of Cibachem will enable the Company to enlarge its customer base in the Middle East Region.
5	Brief details of governmental or any regulatory approvals "required for the acquisition	Approval of the Reserve Bank of India under Foreign Exchange Management Act, 1999 Foreign Exchange Management (Overseas Investment), Rules, Regulations and Directions, 2022 as may be amended from time to time (approval under automatic route).

N. Jhal





# SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

6	Indicative time period for completion of the acquisition	30 <sup>th</sup> September, 2025
7	Nature of Consideration whether Cash consideration or share swap and details of the same	Consideration for acquiring shares of Cibachem to be done in cash.
8	Cost of acquisition or the price at which the shares are acquired.	Rs.55,00,000/- only (Rupees Fifty Five Lakhs only) or its equivalent in UAE Dirhams (AED).
9	Percentage of shareholding control acquired and / or number of shares acquired	300 equity shares of AED 1000/- each (100.00% of the paid-up share capital) of Cibachem from the following shareholders:  1. Mr. Nilesh Harish Thakkar – 225 shares (75%) 2. Mrs. Hina Harish Thakkar – 54 shares (18%) 3. Mr. Benjamin Harish Thakkar – 21 shares (7%)
10	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<u>Brief background:</u>  Cibachem General Trading L.L.C, a limited liability company registered with the Department of Economic Development of the Emirate of Dubai under commercial license no. 696207 and attested by the Notary Public under serial no. 172562/1/2013 on 30 <sup>th</sup> September 2013.  Turnover of Cibachem during the last 3 financial years is given below:  1. Calendar Year 2024 – AED 4,99,250 2. Calendar Year 2023 – AED 3,51,050 3. Calendar Year 2022 – AED 4,92,588

For, Sudarshan Pharma Industries Limited

Nirav Shah

Company Secretary & Compliance Officer

